{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T00:45:43Z","timestamp":1782780343494,"version":"3.54.5"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T00:00:00Z","timestamp":1778025600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T00:00:00Z","timestamp":1782777600000},"content-version":"vor","delay-in-days":55,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"the Kunshan First People's Hospital Medical Science and Technology Innovation Project"},{"name":"the Suzhou Science and Technology Development Plan Guiding Project"},{"name":"the Suzhou Applied Basic Research Science and Technology Innovation Youth Project"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Identifying novel therapeutic targets for pancreatic cancer (PC) is crucial for improving patient outcomes. This study identified the functions, expression, and associated mechanisms of adhesion G protein-coupled receptor G6 (ADGRG6\/ GPR126) in PC. Bioinformatics analyses revealed substantial upregulation of ADGRG6 in human PC, correlating with poor survival rates and advanced tumor stages. Elevated ADGRG6 expression has been observed in human PC tissues and cell lines. Targeted depletion of ADGRG6\n                    <jats:italic>via<\/jats:italic>\n                    the CRISPR\/Cas9 knockout (KO) or lentiviral shRNA technology in established and primary PC cells (priPC-1) resulted in a substantial decrease in cell cycle progression, cell proliferation, viability, as well as reduced migratory and invasive capabilities. Conversely, ADGRG6 overexpression further enhanced the malignant behavior of PC cells. Mechanistically, ADGRG6 is crucial for Akt-mTOR cascade activation. ADGRG6 depletion markedly decreased Akt, S6, and 4E-BP1 phosphorylation. Constitutively active mutant Akt1 (S473D, caAkt1) reversed the anti-proliferative and anti-migratory effects of ADGRG65 shRNA and restored Akt-mTOR phosphorylation. Further analysis revealed that ADGRG6-driven Akt-mTOR activation is mediated by G protein inhibitory subunit 3 (G\u03b1i3). ADGRG6 shRNA significantly inhibited subcutaneous PC xenograft growth in mice, accompanied by reduced Akt-mTOR signaling activation. In contrast, ADGRG6 overexpression promotes xenograft growth. Together, these findings establish ADGRG6 as a critical mediator of PC progression via G\u03b1i3-dependent activation of the Akt-mTOR axis. Targeting ADGRG6 is a promising therapeutic strategy for combating PC.\n                  <\/jats:p>","DOI":"10.1038\/s41419-026-08766-2","type":"journal-article","created":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T14:44:53Z","timestamp":1778078693000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Characterization of ADGRG6 as a potential molecular oncotarget of pancreatic cancer"],"prefix":"10.1038","volume":"17","author":[{"given":"Qian-hui","family":"Gu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4784-3876","authenticated-orcid":false,"given":"Xiao-ren","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-zhuo","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"An-qi","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8595-2518","authenticated-orcid":false,"given":"Yan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9938-2560","authenticated-orcid":false,"given":"Jing-jing","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8946-9945","authenticated-orcid":false,"given":"Ping","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen-yu","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8351-4282","authenticated-orcid":false,"given":"Yuan-yuan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1453-8664","authenticated-orcid":false,"given":"Min-bin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,6]]},"reference":[{"key":"8766_CR1","first-page":"12","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74:12\u201349.","journal-title":"CA Cancer J Clin"},{"key":"8766_CR2","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41575-023-00840-w","volume":"21","author":"ZI Hu","year":"2024","unstructured":"Hu ZI, O\u2019Reilly EM. Therapeutic developments in pancreatic cancer. Nat Rev Gastroenterol Hepatol. 2024;21:7\u201324.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"8766_CR3","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1056\/NEJMoa1809775","volume":"379","author":"T Conroy","year":"2018","unstructured":"Conroy T, Hammel P, Hebbar M, Ben Abdelghani M, Wei AC, Raoul JL, et al. FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer. N Engl J Med. 2018;379:2395\u2013406.","journal-title":"N Engl J Med"},{"key":"8766_CR4","doi-asserted-by":"crossref","unstructured":"Adamska A, Domenichini A, and Falasca M. Pancreatic ductal adenocarcinoma: current and evolving therapies. Int J Mol Sci. 2017;18:1338.","DOI":"10.3390\/ijms18071338"},{"key":"8766_CR5","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1097\/MPA.0b013e31829e2006","volume":"42","author":"H Mahaseth","year":"2013","unstructured":"Mahaseth H, Brutcher E, Kauh J, Hawk N, Kim S, Chen Z, et al. Modified FOLFIRINOX regimen with improved safety and maintained efficacy in pancreatic adenocarcinoma. Pancreas. 2013;42:1311\u20135.","journal-title":"Pancreas"},{"key":"8766_CR6","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","volume":"369","author":"DD Von Hoff","year":"2013","unstructured":"Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369:1691\u2013703.","journal-title":"N Engl J Med"},{"key":"8766_CR7","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1016\/S0140-6736(23)01366-1","volume":"402","author":"ZA Wainberg","year":"2023","unstructured":"Wainberg ZA, Melisi D, Macarulla T, Pazo Cid R, Chandana SR, De La Fouchardiere C, et al. NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial. Lancet. 2023;402:1272\u201381.","journal-title":"Lancet"},{"key":"8766_CR8","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1001\/jamaoncol.2021.0057","volume":"7","author":"M Reyngold","year":"2021","unstructured":"Reyngold M, O\u2019Reilly EM, Varghese AM, Fiasconaro M, Zinovoy M, Romesser PB, et al. Association of ablative radiation therapy with survival among patients with inoperable pancreatic cancer. JAMA Oncol. 2021;7:735\u20138.","journal-title":"JAMA Oncol"},{"key":"8766_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.adro.2020.06.010","volume":"6","author":"C Hassanzadeh","year":"2021","unstructured":"Hassanzadeh C, Rudra S, Bommireddy A, Hawkins WG, Wang-Gillam A, Fields RC, et al. Ablative five-fraction stereotactic body radiation therapy for inoperable pancreatic cancer using online MR-guided adaptation. Adv Radiat Oncol. 2021;6:100506.","journal-title":"Adv Radiat Oncol"},{"key":"8766_CR10","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1146\/annurev-pharmtox-032112-135923","volume":"53","author":"V Katritch","year":"2013","unstructured":"Katritch V, Cherezov V, Stevens RC. Structure-function of the G protein-coupled receptor superfamily. Annu Rev Pharm Toxicol. 2013;53:531\u201356.","journal-title":"Annu Rev Pharm Toxicol"},{"key":"8766_CR11","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.ceb.2014.01.005","volume":"27","author":"M O\u2019Hayre","year":"2014","unstructured":"O\u2019Hayre M, Degese MS, Gutkind JS. Novel insights into G protein and G protein-coupled receptor signaling in cancer. Curr Opin Cell Biol. 2014;27:126\u201335.","journal-title":"Curr Opin Cell Biol"},{"key":"8766_CR12","doi-asserted-by":"publisher","first-page":"1568","DOI":"10.1093\/jnci\/djq363","volume":"102","author":"F Demenais","year":"2010","unstructured":"Demenais F, Mohamdi H, Chaudru V, Goldstein AM, Newton Bishop JA, Bishop DT, et al. Association of MC1R variants and host phenotypes with melanoma risk in CDKN2A mutation carriers: a GenoMEL study. J Natl Cancer Inst. 2010;102:1568\u201383.","journal-title":"J Natl Cancer Inst"},{"key":"8766_CR13","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nrd3320","volume":"10","author":"R Lappano","year":"2011","unstructured":"Lappano R, Maggiolini M. G protein-coupled receptors: novel targets for drug discovery in cancer. Nat Rev Drug Discov. 2011;10:47\u201360.","journal-title":"Nat Rev Drug Discov"},{"key":"8766_CR14","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1007\/s00210-015-1111-8","volume":"388","author":"A Heifetz","year":"2015","unstructured":"Heifetz A, Schertler GF, Seifert R, Tate CG, Sexton PM, Gurevich VV, et al. GPCR structure, function, drug discovery and crystallography: report from Academia-Industry International Conference (UK Royal Society) Chicheley Hall, 1-2 September 2014. Naunyn Schmiedebergs Arch Pharm. 2015;388:883\u2013903.","journal-title":"Naunyn Schmiedebergs Arch Pharm"},{"key":"8766_CR15","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1038\/aps.2011.173","volume":"33","author":"R Zhang","year":"2012","unstructured":"Zhang R, Xie X. Tools for GPCR drug discovery. Acta Pharm Sin. 2012;33:372\u201384.","journal-title":"Acta Pharm Sin"},{"key":"8766_CR16","doi-asserted-by":"publisher","first-page":"431","DOI":"10.3389\/fphar.2018.00431","volume":"9","author":"PA Insel","year":"2018","unstructured":"Insel PA, Sriram K, Wiley SZ, Wilderman A, Katakia T, McCann T, et al. GPCRomics: GPCR expression in cancer cells and tumors identifies new, potential biomarkers and therapeutic targets. Front Pharm. 2018;9:431.","journal-title":"Front Pharm"},{"key":"8766_CR17","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1096\/fj.201700834R","volume":"32","author":"SZ Wiley","year":"2018","unstructured":"Wiley SZ, Sriram K, Liang W, Chang SE, French R, McCann T, et al. GPR68, a proton-sensing GPCR, mediates interaction of cancer-associated fibroblasts and cancer cells. FASEB J. 2018;32:1170\u201383.","journal-title":"FASEB J"},{"key":"8766_CR18","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1124\/pr.114.009647","volume":"67","author":"J Hamann","year":"2015","unstructured":"Hamann J, Aust G, Arac D, Engel FB, Formstone C, Fredriksson R, et al. International Union of Basic and Clinical Pharmacology. XCIV. Adhesion G protein-coupled receptors. Pharm Rev. 2015;67:338\u201367.","journal-title":"Pharm Rev"},{"key":"8766_CR19","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1080\/17460441.2020.1791075","volume":"15","author":"AD Bondarev","year":"2020","unstructured":"Bondarev AD, Attwood MM, Jonsson J, Chubarev VN, Tarasov VV, Schioth HB. Opportunities and challenges for drug discovery in modulating Adhesion G protein-coupled receptor (GPCR) functions. Expert Opin Drug Discov. 2020;15:1291\u2013307.","journal-title":"Expert Opin Drug Discov"},{"key":"8766_CR20","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nature17676","volume":"534","author":"S Nik-Zainal","year":"2016","unstructured":"Nik-Zainal S, Davies H, Staaf J, Ramakrishna M, Glodzik D, Zou X, et al. Landscape of somatic mutations in 560 breast cancer whole-genome sequences. Nature. 2016;534:47\u201354.","journal-title":"Nature"},{"key":"8766_CR21","doi-asserted-by":"publisher","first-page":"246","DOI":"10.4048\/jbc.2017.20.3.246","volume":"20","author":"A Fatima","year":"2017","unstructured":"Fatima A, Tariq F, Malik MFA, Qasim M, Haq F. Copy number profiling of mammaprint genes reveals association with the prognosis of breast cancer patients. J Breast Cancer. 2017;20:246\u201353.","journal-title":"J Breast Cancer"},{"key":"8766_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-13929-1","volume":"11","author":"S Shuai","year":"2020","unstructured":"Shuai S, Drivers P, Functional Interpretation Working G, Gallinger S, Stein LD, Consortium P. Combined burden and functional impact tests for cancer driver discovery using DriverPower. Nat Commun. 2020;11:734.","journal-title":"Nat Commun"},{"key":"8766_CR23","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1158\/1541-7786.MCR-18-0363","volume":"17","author":"S Garinet","year":"2019","unstructured":"Garinet S, Pignot G, Vacher S, Le Goux C, Schnitzler A, Chemlali W, et al. High Prevalence of a hotspot of noncoding somatic mutations in intron 6 of GPR126 in bladder cancer. Mol Cancer Res. 2019;17:469\u201375.","journal-title":"Mol Cancer Res"},{"key":"8766_CR24","doi-asserted-by":"publisher","first-page":"34871","DOI":"10.1074\/jbc.M114.571000","volume":"289","author":"H Cui","year":"2014","unstructured":"Cui H, Wang Y, Huang H, Yu W, Bai M, Zhang L, et al. GPR126 protein regulates developmental and pathological angiogenesis through modulation of VEGFR2 receptor signaling. J Biol Chem. 2014;289:34871\u201385.","journal-title":"J Biol Chem"},{"key":"8766_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-08576-5","volume":"10","author":"S Wu","year":"2019","unstructured":"Wu S, Ou T, Xing N, Lu J, Wan S, Wang C, et al. Whole-genome sequencing identifies ADGRG6 enhancer mutations and FRS2 duplications as angiogenesis-related drivers in bladder cancer. Nat Commun. 2019;10:720.","journal-title":"Nat Commun"},{"key":"8766_CR26","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-019-5948-y","volume":"19","author":"S Xu","year":"2019","unstructured":"Xu S, Wang W, Xu C, Li X, Ye J, Zhu Y, et al. ROS1-ADGRG6: a case report of a novel ROS1 oncogenic fusion variant in lung adenocarcinoma and the response to crizotinib. BMC Cancer. 2019;19:769.","journal-title":"BMC Cancer"},{"key":"8766_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2016.36","volume":"6","author":"A Maiga","year":"2016","unstructured":"Maiga A, Lemieux S, Pabst C, Lavallee VP, Bouvier M, Sauvageau G, et al. Transcriptome analysis of G protein-coupled receptors in distinct genetic subgroups of acute myeloid leukemia: identification of potential disease-specific targets. Blood Cancer J. 2016;6:e431.","journal-title":"Blood Cancer J"},{"key":"8766_CR28","doi-asserted-by":"publisher","first-page":"1798","DOI":"10.1111\/cas.14868","volume":"112","author":"H Cui","year":"2021","unstructured":"Cui H, Yu W, Yu M, Luo Y, Yang M, Cong R, et al. GPR126 regulates colorectal cancer cell proliferation by mediating HDAC2 and GLI2 expression. Cancer Sci. 2021;112:1798\u2013810.","journal-title":"Cancer Sci"},{"key":"8766_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-021-04205-6","volume":"12","author":"Y Sun","year":"2021","unstructured":"Sun Y, Xie J, Cai S, Wang Q, Feng Z, Li Y, et al. Elevated expression of nuclear receptor-binding SET domain 3 promotes pancreatic cancer cell growth. Cell Death Dis. 2021;12:913.","journal-title":"Cell Death Dis"},{"key":"8766_CR30","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.canlet.2020.02.018","volume":"476","author":"J Zheng","year":"2020","unstructured":"Zheng J, Zhang Y, Cai S, Dong L, Hu X, Chen MB, et al. MicroRNA-4651 targets bromodomain-containing protein 4 to inhibit non-small cell lung cancer cell progression. Cancer Lett. 2020;476:129\u201339.","journal-title":"Cancer Lett"},{"key":"8766_CR31","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1158\/1535-7163.MCT-17-1094","volume":"17","author":"MB Chen","year":"2018","unstructured":"Chen MB, Liu YY, Xing ZY, Zhang ZQ, Jiang Q, Lu PH, et al. Itraconazole-induced inhibition on human esophageal cancer cell growth requires AMPK activation. Mol Cancer Ther. 2018;17:1229\u201339.","journal-title":"Mol Cancer Ther"},{"key":"8766_CR32","first-page":"217","volume":"14","author":"G Xu","year":"2023","unstructured":"Xu G, Qi LN, Zhang MQ, Li XY, Chai JL, Zhang ZQ, et al. Galphai1\/3 mediation of Akt-mTOR activation is important for RSPO3-induced angiogenesis. Protein Cell. 2023;14:217\u201322.","journal-title":"Protein Cell"},{"key":"8766_CR33","first-page":"223","volume":"14","author":"F Liu","year":"2023","unstructured":"Liu F, Chen G, Zhou LN, Wang Y, Zhang ZQ, Qin X, et al. YME1L overexpression exerts pro-tumorigenic activity in glioma by promoting Galphai1 expression and Akt activation. Protein Cell. 2023;14:223\u20139.","journal-title":"Protein Cell"},{"key":"8766_CR34","doi-asserted-by":"publisher","first-page":"8535","DOI":"10.7150\/thno.61452","volume":"11","author":"Y Wang","year":"2021","unstructured":"Wang Y, Liu YY, Chen MB, Cheng KW, Qi LN, Zhang ZQ, et al. Neuronal-driven glioma growth requires Galphai1 and Galphai3. Theranostics. 2021;11:8535\u201349.","journal-title":"Theranostics"},{"key":"8766_CR35","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-024-07079-6","volume":"15","author":"JZ Jiang","year":"2024","unstructured":"Jiang JZ, Qiao YB, Zhu XR, Gu QH, Lu JJ, Ye ZY, et al. Identification of Galphai3 as a promising molecular oncotarget of pancreatic cancer. Cell Death Dis. 2024;15:699.","journal-title":"Cell Death Dis"},{"key":"8766_CR36","doi-asserted-by":"publisher","DOI":"10.1002\/adbi.201900236","volume":"5","author":"X Liu","year":"2021","unstructured":"Liu X, Li Z, Wang Y. Advances in targeted therapy and immunotherapy for pancreatic cancer. Adv Biol (Weinh). 2021;5:e1900236.","journal-title":"Adv Biol (Weinh)"},{"key":"8766_CR37","first-page":"17","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73:17\u201348.","journal-title":"CA Cancer J Clin"},{"key":"8766_CR38","doi-asserted-by":"publisher","first-page":"e214708","DOI":"10.1001\/jamanetworkopen.2021.4708","volume":"4","author":"L Rahib","year":"2021","unstructured":"Rahib L, Wehner MR, Matrisian LM, Nead KT. Estimated projection of US cancer incidence and death to 2040. JAMA Netw Open. 2021;4:e214708.","journal-title":"JAMA Netw Open"},{"key":"8766_CR39","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1126\/science.1176009","volume":"326","author":"RO Hynes","year":"2009","unstructured":"Hynes RO. The extracellular matrix: not just pretty fibrils. Science. 2009;326:1216\u20139.","journal-title":"Science"},{"key":"8766_CR40","doi-asserted-by":"publisher","DOI":"10.1017\/erm.2021.26","volume":"23","author":"D Cao","year":"2021","unstructured":"Cao D, Song Q, Li J, Jiang Y, Wang Z, Lu S. Opportunities and challenges in targeted therapy and immunotherapy for pancreatic cancer. Expert Rev Mol Med. 2021;23:e21.","journal-title":"Expert Rev Mol Med"},{"key":"8766_CR41","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1245\/s10434-020-09367-9","volume":"28","author":"FG Rocha","year":"2021","unstructured":"Rocha FG. Landmark series: immunotherapy and targeted therapy for pancreatic cancer. Ann Surg Oncol. 2021;28:1400\u20136.","journal-title":"Ann Surg Oncol"},{"key":"8766_CR42","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.ejphar.2018.07.034","volume":"834","author":"YT Lee","year":"2018","unstructured":"Lee YT, Tan YJ, Oon CE. Molecular targeted therapy: treating cancer with specificity. Eur J Pharm. 2018;834:188\u201396.","journal-title":"Eur J Pharm"},{"key":"8766_CR43","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2117004119","volume":"119","author":"W An","year":"2022","unstructured":"An W, Lin H, Ma L, Zhang C, Zheng Y, Cheng Q, et al. Progesterone activates GPR126 to promote breast cancer development via the Gi pathway. Proc Natl Acad Sci USA. 2022;119:e2117004119.","journal-title":"Proc Natl Acad Sci USA"},{"key":"8766_CR44","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-27675-4","volume":"13","author":"L Baxter","year":"2023","unstructured":"Baxter L, Gordon NS, Ott S, Wang J, Patel P, Goel A, et al. Properties of non-coding mutation hotspots as urinary biomarkers for bladder cancer detection. Sci Rep. 2023;13:1060.","journal-title":"Sci Rep"},{"key":"8766_CR45","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-023-10653-4","volume":"23","author":"Y Gu","year":"2023","unstructured":"Gu Y, Hua Q, Li Z, Zhang X, Lou C, Zhang Y, et al. Diagnostic value of combining preoperative inflammatory markers ratios with CA199 for patients with early-stage pancreatic cancer. BMC Cancer. 2023;23:227.","journal-title":"BMC Cancer"},{"key":"8766_CR46","first-page":"383","volume":"31","author":"XF Lei","year":"2017","unstructured":"Lei XF, Jia SZ, Ye J, Qiao YL, Zhao GM, Li XH, et al. Application values of detection of serum CA199, CA242 and CA50 in the diagnosis of pancreatic cancer. J Biol Regul Homeost Agents. 2017;31:383\u20138.","journal-title":"J Biol Regul Homeost Agents"},{"key":"8766_CR47","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1186\/s12957-023-03080-z","volume":"21","author":"T Xia","year":"2023","unstructured":"Xia T, Xu P, Mou Y, Zhang X, Song S, Zhou Y, et al. Factors predicting recurrence after left\u2011sided pancreatectomy for pancreatic ductal adenocarcinoma. World J Surg Oncol. 2023;21:191.","journal-title":"World J Surg Oncol"},{"key":"8766_CR48","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-023-05684-5","volume":"14","author":"SQ Peng","year":"2023","unstructured":"Peng SQ, Zhu XR, Zhao MZ, Zhang YF, Wang AR, Chen MB, et al. Identification of matrix-remodeling associated 5 as a possible molecular oncotarget of pancreatic cancer. Cell Death Dis. 2023;14:157.","journal-title":"Cell Death Dis"},{"key":"8766_CR49","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-021-04201-w","volume":"12","author":"XR Zhu","year":"2021","unstructured":"Zhu XR, Peng SQ, Wang L, Chen XY, Feng CX, Liu YY, et al. Identification of phosphoenolpyruvate carboxykinase 1 as a potential therapeutic target for pancreatic cancer. Cell Death Dis. 2021;12:918.","journal-title":"Cell Death Dis"},{"key":"8766_CR50","doi-asserted-by":"publisher","DOI":"10.1177\/17588359241284911","volume":"16","author":"AJ Ouissam","year":"2024","unstructured":"Ouissam AJ, Hind C, Sami Aziz B, Said A. Inhibition of the PI3K\/AKT\/mTOR pathway in pancreatic cancer: is it a worthwhile endeavor? Ther Adv Med Oncol. 2024;16:17588359241284911.","journal-title":"Ther Adv Med Oncol"},{"key":"8766_CR51","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.jbior.2015.06.003","volume":"59","author":"TL Fitzgerald","year":"2015","unstructured":"Fitzgerald TL, Lertpiriyapong K, Cocco L, Martelli AM, Libra M, Candido S, et al. Roles of EGFR and KRAS and their downstream signaling pathways in pancreatic cancer and pancreatic cancer stem cells. Adv Biol Regul. 2015;59:65\u201381.","journal-title":"Adv Biol Regul"},{"key":"8766_CR52","doi-asserted-by":"publisher","first-page":"24753","DOI":"10.18632\/aging.203713","volume":"13","author":"Y Xiao","year":"2021","unstructured":"Xiao Y, Liu Y, Gao Z, Li X, Weng M, Shi C, et al. Fisetin inhibits the proliferation, migration and invasion of pancreatic cancer by targeting PI3K\/AKT\/mTOR signaling. Aging. 2021;13:24753\u201367.","journal-title":"Aging"},{"key":"8766_CR53","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellsig.2023.110642","volume":"106","author":"J Chen","year":"2023","unstructured":"Chen J, Liu F, Wu J, Yang Y, He J, Wu F, et al. Effect of STK3 on proliferation and apoptosis of pancreatic cancer cells via PI3K\/AKT\/mTOR pathway. Cell Signal. 2023;106:110642.","journal-title":"Cell Signal"},{"key":"8766_CR54","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-024-03444-9","volume":"24","author":"L Huang","year":"2024","unstructured":"Huang L, Sun J, Ma Y, Chen H, Tian C, Dong M. MSI2 regulates NLK-mediated EMT and PI3K\/AKT\/mTOR pathway to promote pancreatic cancer progression. Cancer Cell Int. 2024;24:273.","journal-title":"Cancer Cell Int"},{"key":"8766_CR55","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.2174\/0929867324666170206142658","volume":"24","author":"S Ebrahimi","year":"2017","unstructured":"Ebrahimi S, Hosseini M, Shahidsales S, Maftouh M, Ferns GA, Ghayour-Mobarhan M, et al. Targeting the Akt\/PI3K signaling pathway as a potential therapeutic strategy for the treatment of pancreatic cancer. Curr Med Chem. 2017;24:1321\u201331.","journal-title":"Curr Med Chem"},{"key":"8766_CR56","doi-asserted-by":"crossref","unstructured":"Wilde C, Chaudhry P M, Luo R, Simon K U, Piao X, and Liebscher I. Collagen VI Is a Gi-Biased Ligand of the Adhesion GPCR GPR126\/ADGRG6. Cells. 2023;12:1551.","DOI":"10.3390\/cells12111551"},{"key":"8766_CR57","doi-asserted-by":"publisher","first-page":"ra76","DOI":"10.1126\/scisignal.2005347","volume":"7","author":"KJ Paavola","year":"2014","unstructured":"Paavola KJ, Sidik H, Zuchero JB, Eckart M, Talbot WS. Type IV collagen is an activating ligand for the adhesion G protein-coupled receptor GPR126. Sci Signal. 2014;7:ra76.","journal-title":"Sci Signal"},{"key":"8766_CR58","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1016\/j.neuron.2014.12.057","volume":"85","author":"SC Petersen","year":"2015","unstructured":"Petersen SC, Luo R, Liebscher I, Giera S, Jeong SJ, Mogha A, et al. The adhesion GPCR GPR126 has distinct, domain-dependent functions in Schwann cell development mediated by interaction with laminin-211. Neuron. 2015;85:755\u201369.","journal-title":"Neuron"},{"key":"8766_CR59","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-13-154","volume":"13","author":"D Ohlund","year":"2013","unstructured":"Ohlund D, Franklin O, Lundberg E, Lundin C, Sund M. Type IV collagen stimulates pancreatic cancer cell proliferation, migration, and inhibits apoptosis through an autocrine loop. BMC Cancer. 2013;13:154.","journal-title":"BMC Cancer"},{"key":"8766_CR60","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1038\/s41573-025-01139-y","volume":"24","author":"JS Lorente","year":"2025","unstructured":"Lorente JS, Sokolov AV, Ferguson G, Schioth HB, Hauser AS, Gloriam DE. GPCR drug discovery: new agents, targets and indications. Nat Rev Drug Discov. 2025;24:458\u201379.","journal-title":"Nat Rev Drug Discov"},{"key":"8766_CR61","doi-asserted-by":"publisher","first-page":"e14047","DOI":"10.1371\/journal.pone.0014047","volume":"5","author":"H Waller-Evans","year":"2010","unstructured":"Waller-Evans H, Promel S, Langenhan T, Dixon J, Zahn D, Colledge WH, et al. The orphan adhesion-GPCR GPR126 is required for embryonic development in the mouse. PLoS One. 2010;5:e14047.","journal-title":"PLoS One"},{"key":"8766_CR62","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1111\/nyas.14135","volume":"1456","author":"G Musa","year":"2019","unstructured":"Musa G, Cazorla-Vazquez S, van Amerongen MJ, Stemmler MP, Eckstein M, Hartmann A, et al. Gpr126 (Adgrg6) is expressed in cell types known to be exposed to mechanical stimuli. Ann N Y Acad Sci. 2019;1456:96\u2013108.","journal-title":"Ann N Y Acad Sci"},{"key":"8766_CR63","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1126\/science.1173474","volume":"325","author":"KR Monk","year":"2009","unstructured":"Monk KR, Naylor SG, Glenn TD, Mercurio S, Perlin JR, Dominguez C, et al. A G protein-coupled receptor is essential for Schwann cells to initiate myelination. Science. 2009;325:1402\u20135.","journal-title":"Science"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08766-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08766-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08766-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T00:02:49Z","timestamp":1782777769000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08766-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,6]]},"references-count":63,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8766"],"URL":"https:\/\/doi.org\/10.1038\/s41419-026-08766-2","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,6]]},"assertion":[{"value":"1 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was approved by Ethics Review Board of the Affiliated Kunshan Hospital of Jiangsu University.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"604"}}